Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
- decodeMR Team
- 8 hours ago
- 1 min read
08/07/2026
Merck announced that the US FDA had granted Breakthrough Therapy designation to enpatoran (Ref)
Merck announced that the US FDA had granted Breakthrough Therapy designation to enpatoran (TLR 7/8 inhibitor) for the treatment of lupus with active cutaneous manifestations.
The FDA Breakthrough Therapy designation was supported by results from the Phase 2, WILLOW study, which demonstrated meaningful symptoms improvement, particularly among patients with active cutaneous manifestations.
The trial used an innovative basket and adaptive study design including patients with both CLE and SLE.
Merck recently initiated the ELOWEN 1 and ELOWEN 2 studies, evaluating the therapy’s impact on both cutaneous and systemic symptoms in patients with lupus and potential links between skin and systemic disease activity.
Chemomab Therapeutics and Scipher Medicine announced a merger to advance nebokitug in an AI-powered Phase 2 Rheumatoid Arthritis study (Ref)
Chemomab Therapeutics and Scipher Medicine announced a definitive merger agreement to advance nebokitug (anti-CCL24) into an AI-powered Phase 2 precision medicine trial for rheumatoid arthritis (RA).
The combined company would use Scipher's AI-driven precision medicine platform to identify RA patients most likely to respond to nebokitug and the Phase 2 trial was expected to read out in H1 2028.
The Combined company was valued at $150 million before a concurrent $30 million private placement with cash runway into H2 2028.
